Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

Verrica Pharmaceuticals (Nasdaq: VRCA) will host a conference call and live webcast at 4:30 p.m. ET on Thursday, August 6, 2026, to discuss second quarter 2026 financial results and provide a corporate update.

Rhea-AI Summary

Verrica Pharmaceuticals (Nasdaq: VRCA) will host a conference call and live webcast at 4:30 p.m. ET on Thursday, August 6, 2026, to discuss second quarter 2026 financial results and provide a corporate update. Participants can join via domestic dial-in 1-800-225-9448, international 1-203-518-9708, using conference ID: VERRICA, or through the investor relations section of the company website.

A replay of the webcast will be archived on Verrica’s website for 90 days. Verrica develops and commercializes treatments for dermatological diseases, including FDA-approved YCANTH (VP-102) for molluscum contagiosum, and is developing YCANTH for common warts and VP-315 under license from Lytix Biopharma for non-melanoma skin cancers.

Argus Jul 30 session 2 alerts

+1.54% close to close 0.2x rel. volume Open Argus

Details

News Market Reaction – VRCA

$97.42M Mkt Cap at Peak Alert

On Jul 30, the day this news came out, VRCA closed 1.54% above the previous close. Our momentum scanner recorded 2 alerts for this stock that day.

Data tracked by StockTitan Argus for the Jul 30 session.

Key Figures

Reporting period end: June 30, 2026 Conference call date: August 6, 2026 Conference call time: 4:30 p.m. ET +3 more

Reporting period end

June 30, 2026

Second quarter financial results

Conference call date

August 6, 2026

Second-quarter results and corporate update

Conference call time

4:30 p.m. ET

August 6, 2026

Webcast replay period

90 days

Following the event

U.S. affected population

6 million people

Molluscum contagiosum

Approved patient age

2 years and older

FDA-approved YCANTH treatment

Previous Earnings date Reports

2 past events · Latest: May 05

Same Type 2 events

1. May 05

   First-quarter report date

   24h Move

   +12.6%

   Announcement scheduled first-quarter results and a corporate update for May 12

2. Mar 05

   Fourth-quarter report date

   24h Move

   -2.4%

   Announcement scheduled fourth-quarter and full-year results for March 11

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

molluscum contagiosum, cantharidin, basal cell carcinoma, squamous cell carcinoma

4 terms

molluscum contagiosum medical

"treatment for adult and pediatric patients two years of age and older with molluscum contagiosum"

Molluscum contagiosum is a common viral skin infection that causes small, painless bumps or lesions on the skin. While it primarily affects children and healthy adults, it can spread easily through skin contact. For investors, understanding health conditions like this highlights the importance of healthcare companies involved in treatments and the potential impact of infectious diseases on public health and economic stability.

cantharidin medical

"YCANTH® (VP-102) (cantharidin), is the first and only"

A naturally occurring blistering chemical produced by certain beetles, used historically and in medicine as a topical agent to remove warts and lesions and investigated as a raw material for drug development. It matters to investors because companies that manufacture, reformulate, or develop therapies involving cantharidin face regulatory review, manufacturing and safety controls, potential liability, and market opportunity tied to clinical results and approvals; think of it as a powerful, concentrated skin irritant used under medical oversight like a targeted chemical peel.

basal cell carcinoma medical

"non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma"

A type of skin cancer that starts in the cells at the bottom layer of the skin and usually grows slowly and stays local rather than spreading to other organs. It matters to investors because its high frequency and generally surgical treatment drive steady demand for diagnostics, procedures, topical or surgical products, and follow‑on therapies, while new drugs, devices or regulatory approvals can shift market value and reimbursement dynamics. Think of it as a common maintenance issue whose repair options and costs influence healthcare spending and related businesses.

squamous cell carcinoma medical

"including basal cell carcinoma and squamous cell carcinoma"

Squamous cell carcinoma is a type of skin cancer that develops when the cells in the outer layer of the skin grow abnormally and uncontrollably. It can also occur in other parts of the body, such as the mouth or throat. For investors, understanding diseases like this is important because they can impact healthcare companies, influence medical research funding, and affect overall public health trends.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WEST CHESTER, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Thursday, August 6, 2026, to discuss the Company's financial results for the second quarter ending June 30, 2026, and provide a corporate update.

Individuals may participate in the live call via telephone by dialing 1-800-225-9448 (domestic) or 1-203-518-9708 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register.

A live audio webcast of the call can also be accessed by visiting the investor relations section of the Company’s website, www.verrica.com, or by clicking here. A replay of the webcast will be archived on Verrica’s website for 90 days following the event.

About Verrica Pharmaceuticals Inc. 
Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

John J Kirby 
Interim Chief Financial Officer 
jkirby@verrica.com

Kevin Gardner 
LifeSci Advisors 
kgardner@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Verrica Pharmaceuticals (VRCA) report its Q2 2026 financial results?

Verrica Pharmaceuticals will discuss its Q2 2026 financial results on a conference call at 4:30 p.m. ET on August 6, 2026. According to Verrica, the call will also include a broader corporate update for investors and analysts.

How can investors join Verrica Pharmaceuticals' Q2 2026 earnings call for VRCA?

Investors can join Verrica’s Q2 2026 call by dialing 1-800-225-9448 (domestic) or 1-203-518-9708 (international) with conference ID VERRICA. According to Verrica, participants should dial in 10 minutes early to register before the call starts.

Will Verrica Pharmaceuticals (VRCA) provide a webcast and replay for the August 6, 2026 call?

Yes, Verrica will provide a live audio webcast via the investor relations section of www.verrica.com. According to Verrica, a replay of the webcast will be archived on the company’s website for 90 days following the August 6, 2026 event.

What does Verrica Pharmaceuticals (VRCA) do in dermatology?

Verrica Pharmaceuticals develops and commercializes medications for dermatological diseases, including certain skin cancers. According to Verrica, its portfolio includes the FDA-approved treatment YCANTH (VP-102) for molluscum contagiosum and pipeline programs targeting common warts and non-melanoma skin cancers such as basal cell and squamous cell carcinoma.

What is YCANTH (VP-102) from Verrica Pharmaceuticals (VRCA)?

YCANTH (VP-102) is a cantharidin-based treatment administered by healthcare professionals for molluscum contagiosum. According to Verrica, it is the first and only FDA-approved treatment for adult and pediatric patients aged two years and older with this highly contagious viral skin infection.

What is VP-315 and Verrica Pharmaceuticals' agreement with Lytix Biopharma for VRCA?

VP-315 (ruxotemitide) is being developed for non-melanoma skin cancers, including basal and squamous cell carcinoma. According to Verrica, it holds a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 in these dermatologic oncology indications.